1.04 USD
▼-0.01-0.95%
盘后 1.11 0.00%
2026-09-16
市值
$9.96M
市盈率
—
EPS
-1.48
股息率
—
52 周区间
0.88 – 2.73
成交量
27.54K
Beta
0.30
目标价
6.25
52W 低 0.8852W 高 2.73
价格走势
公司简介
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinic...